Standard BioTools Sells Mass Cytometry Unit, Gets $30M Illumina Buyout to Clear Path for Treeline Merger
LAB is trading near its 52-week low of $0.703 (13% above the low).
Summary
Standard BioTools sold its Mass Cytometry business for up to $10M and received $30M from Illumina to buy out contingent payments, both moves designed to clear the path for its reverse merger with Treeline Biosciences.
Key Events · M&A and Partnerships · LAB
-
Illumina Buyout of Contingent Payments
Standard BioTools received $30 million cash from Illumina to fully satisfy and discharge all 2026 earnout and future royalty obligations from the SomaLogic sale, boosting pro forma net cash for the Treeline merger exchange ratio.
-
Mass Cytometry Business Sold
The Mass Cytometry unit (CyTOF, Hyperion) was sold to Multiplex Bio for up to $10 million — a $5 million seller note plus a potential $5 million milestone — with Standard BioTools also providing up to a $10 million working capital loan at closing.
-
HSR Antitrust Clearance Received
The U.S. Federal Trade Commission granted early termination of the Hart-Scott-Rodino waiting period for the Treeline merger, removing a regulatory condition.
-
Transactions Tied to Treeline Merger Close
Both the Illumina buyout and the Mass Cytometry sale are conditioned on stockholder approval and the closing of the Treeline reverse merger, expected by end of 2026.
Analysis · LAB · Life Sciences
Standard BioTools took two concrete steps to streamline its business ahead of the pending reverse merger with Treeline Biosciences. It sold its Mass Cytometry business to Multiplex Bio for up to $10 million in a seller note plus a potential milestone, and it received $30 million cash from Illumina to buy out all remaining earnout and royalty obligations from the prior SomaLogic sale. The Illumina cash boosts the pro forma net cash position used to calculate the exchange ratio in the Treeline deal, directly benefiting Standard BioTools shareholders. The Mass Cytometry divestiture removes a non-core asset and provides a potential future payout, though the upfront consideration is a note, not cash. Both transactions are conditioned on stockholder approval and the closing of the Treeline merger, expected by end of 2026. The early HSR clearance removes a regulatory hurdle, keeping the merger on track.
At the time of this filing, LAB was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $303.2M. The 52-week trading range was $0.70 to $1.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.